Patient outcomes
| Diagnosis . | ALL . | CML . |
|---|---|---|
| Imatinib outcomes | ||
| Median day therapy began after HCT (range) | 27 (21-39) | 29 (25-34) |
| Median duration of therapy, d (range) | 334 (44-426) | 352 (180-375) |
| Average daily dose before day 90, mg (range)* | 389 (135-400) | 400 (286-502) |
| Average no. of d/wk before day 90 (range) | 6.9 (4.8-7.0) | 7.0 (5.0-7.0) |
| Average daily dose after day 90, mg (range)† | 400 (199-671) | 400 (400-450) |
| No. completed therapy | 13 | 6 |
| No. continuing therapy | 2 | 0 |
| Survival | ||
| No. alive | 12 | 6 |
| No. deceased | 3 | 1 |
| Median duration, y (range) | 1.31 (0.74-2.6) | 1.43 (0.91-2.7) |
| Diagnosis . | ALL . | CML . |
|---|---|---|
| Imatinib outcomes | ||
| Median day therapy began after HCT (range) | 27 (21-39) | 29 (25-34) |
| Median duration of therapy, d (range) | 334 (44-426) | 352 (180-375) |
| Average daily dose before day 90, mg (range)* | 389 (135-400) | 400 (286-502) |
| Average no. of d/wk before day 90 (range) | 6.9 (4.8-7.0) | 7.0 (5.0-7.0) |
| Average daily dose after day 90, mg (range)† | 400 (199-671) | 400 (400-450) |
| No. completed therapy | 13 | 6 |
| No. continuing therapy | 2 | 0 |
| Survival | ||
| No. alive | 12 | 6 |
| No. deceased | 3 | 1 |
| Median duration, y (range) | 1.31 (0.74-2.6) | 1.43 (0.91-2.7) |